SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis, F. Spertini, EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders, Allergy, 2015, 70,
  2. 2
    Peter Valent, Cem Akin, Michel Arock, Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis, Current Treatment Options in Allergy, 2014, 1, 3, 247

    CrossRef

  3. 3
    J.-P. Oster, F. Lavaud, A. Bentaleb, Y. Bloch, J.-L. Bourrain, P. Carré, G. Devouassoux, G. Newinger, M. Verdaguer, F. de Blay, Intérêt d’un traitement par omalizumab dans le cadre d’une immunothérapie spécifique. Recueil d’expérience et analyse de la littérature, Revue Française d'Allergologie, 2014, 54, 5, 347

    CrossRef

  4. 4
    Cem Akin, Mast Cell Activation Disorders, The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2, 3, 252

    CrossRef

  5. 5
    Kristin C. Sokol, Aasia Ghazi, Brent C. Kelly, J. Andrew Grant, Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis: A Review of the Literature and Case Report, The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2, 3, 266

    CrossRef

  6. 6
    Hector Rodriguez, John Fahrenholz, Omalizumab Treatment for Prevention of Anaphylaxis, Current Treatment Options in Allergy, 2014, 1, 3, 278

    CrossRef

  7. 7
    Jaechun Lee, Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy, Asia Pacific Allergy, 2014, 4, 2, 126

    CrossRef

  8. 8
    Evelyn M. Slaughter, Nathan Boyer, Steven Bennett, The Bee Sting That Was Not: An Unusual Case of Hymenoptera Anaphylaxis Averted in a Patient Treated with Omalizumab for Asthma, Case Reports in Medicine, 2014, 2014, 1

    CrossRef

  9. 9
    Frank Siebenhaar, Cem Akin, Carsten Bindslev-Jensen, Marcus Maurer, Sigurd Broesby-Olsen, Treatment Strategies in Mastocytosis, Immunology and Allergy Clinics of North America, 2014, 34, 2, 433

    CrossRef

  10. 10
    D. Wieczorek, A. Kapp, B. Wedi, Unverträglichkeit der spezifischen Immuntherapie mit Hymenopterengift, Der Hautarzt, 2014, 65, 9, 791

    CrossRef

  11. 11
    Elizabeth Nicole da Silva, Katrina Louise Randall, Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome, The Journal of Allergy and Clinical Immunology: In Practice, 2013, 1, 6, 687

    CrossRef

  12. 12
    J. Sanchez, R. Ramirez, S. Diez, S. Sus, A. Echenique, M. Olivares, R. Cardona, Omalizumab beyond asthma, Allergologia et Immunopathologia, 2012, 40, 5, 306

    CrossRef

  13. 13
    M. Drouet, Tryptase et mastocytose dans l’allergie aux venins d’hyménoptères, Revue Française d'Allergologie, 2012, 52, 3, 148

    CrossRef

  14. 14
    D.-A. Moneret-Vautrin, Immunothérapie sublinguale et orale de l’allergie alimentaire : effets cliniques et signification des modifications immunologiques, Revue Française d'Allergologie, 2011, 51, 3, 286

    CrossRef

  15. 15
    M. V. Kopp, Role of immunmodulators in allergen-specific immunotherapy, Allergy, 2011, 66, 6
  16. 16
    Kalliopi Kontou-Fili, Christos I. Filis, Christina Voulgari, Panayiotis G. Panayiotidis, Omalizumab monotherapy for bee sting and unprovoked “anaphylaxis” in a patient with systemic mastocytosis and undetectable specific IgE, Annals of Allergy, Asthma & Immunology, 2010, 104, 6, 537

    CrossRef